NO20061049L - Krystallformer av Azithromycin - Google Patents

Krystallformer av Azithromycin

Info

Publication number
NO20061049L
NO20061049L NO20061049A NO20061049A NO20061049L NO 20061049 L NO20061049 L NO 20061049L NO 20061049 A NO20061049 A NO 20061049A NO 20061049 A NO20061049 A NO 20061049A NO 20061049 L NO20061049 L NO 20061049L
Authority
NO
Norway
Prior art keywords
azithromycin
crystal forms
infections
treatment
new crystal
Prior art date
Application number
NO20061049A
Other languages
English (en)
Inventor
Zheng Jane Li
Andrew Trask
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061049(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20061049L publication Critical patent/NO20061049L/no
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Det beskrives nye krystallformer av azithromycin og antibiotika egnet ved behandlingen av infeksjoner.
NO20061049A 2001-05-22 2006-03-03 Krystallformer av Azithromycin NO20061049L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29256501P 2001-05-22 2001-05-22
US29774101P 2001-06-12 2001-06-12
US34304101P 2001-12-21 2001-12-21
PCT/IB2002/001570 WO2002094843A1 (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin

Publications (1)

Publication Number Publication Date
NO20061049L true NO20061049L (no) 2003-05-12

Family

ID=27404135

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20035177A NO321894B1 (no) 2001-05-22 2003-11-21 Krystallinsk form av azithromycin
NO20061049A NO20061049L (no) 2001-05-22 2006-03-03 Krystallformer av Azithromycin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20035177A NO321894B1 (no) 2001-05-22 2003-11-21 Krystallinsk form av azithromycin

Country Status (35)

Country Link
US (10) US6977243B2 (no)
EP (1) EP1390377B1 (no)
JP (3) JP2004530703A (no)
KR (1) KR100574153B1 (no)
AP (1) AP2003002906A0 (no)
AR (1) AR036022A1 (no)
AT (2) ATE404575T1 (no)
AU (1) AU2002256846B2 (no)
BG (1) BG108370A (no)
BR (1) BR0209918A (no)
CA (1) CA2391659C (no)
CR (1) CR7159A (no)
CZ (1) CZ20033154A3 (no)
DE (2) DE60228345D1 (no)
DK (1) DK1390377T3 (no)
EA (2) EA007618B1 (no)
EE (1) EE200300575A (no)
ES (2) ES2310886T3 (no)
GE (1) GEP20084399B (no)
HU (1) HUP0400446A2 (no)
IL (1) IL158591A0 (no)
IS (1) IS7007A (no)
MA (1) MA27023A1 (no)
MX (1) MXPA03010028A (no)
MY (1) MY129319A (no)
NO (2) NO321894B1 (no)
NZ (2) NZ539801A (no)
PA (1) PA8545701A1 (no)
PE (1) PE20021064A1 (no)
PL (1) PL367091A1 (no)
PT (1) PT1390377E (no)
SK (1) SK14402003A3 (no)
TN (1) TNSN03121A1 (no)
WO (1) WO2002094843A1 (no)
YU (1) YU91603A (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
AU768219B2 (en) * 1998-11-30 2003-12-04 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
WO2002015842A2 (en) * 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
DK1390377T3 (da) * 2001-05-22 2006-06-19 Pfizer Prod Inc Ny krystalform af azithromycin
ITMI20011762A1 (it) 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
PL371259A1 (pl) * 2001-12-21 2005-06-13 Pfizer Products Inc. Bezpośrednio sprasowywalne preparaty azytromycyny
AU2002353316A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Methods for wet granulating azithromycin
BR0307331A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formulações granuladas a seco de azitromicina
HRP20020614A2 (en) 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
CA2422972A1 (en) * 2003-03-21 2004-09-21 Apotex Inc. Isopropanolate of azithromycin and method of manufacturing
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1878432A1 (en) * 2003-07-24 2008-01-16 Pliva - Research and Development Ltd. Single dose fast dissolving azithromycin
EP1648473B1 (en) 2003-07-24 2009-01-28 PLIVA HRVATSKA d.o.o. Single dose fast dissolving azithromycin
CA2678125C (en) * 2003-11-17 2014-10-14 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US20050250714A1 (en) * 2004-05-06 2005-11-10 Lin Kangwen L Crystalline forms of 9-(S)-erythromycylamine
JP2008501657A (ja) * 2004-06-02 2008-01-24 サンド・アクチエンゲゼルシヤフト 結晶形態のメロペネム中間体
US7683162B2 (en) 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
US8495244B2 (en) * 2005-06-29 2013-07-23 Jumpstart Wireless Corporation System and method for dynamic automatic communication path selection, distributed device synchronization and task delegation
US7750153B2 (en) * 2005-07-05 2010-07-06 Hetero Drugs Limited Process for the preparation of didanosine using novel intermediates
EP1904510A1 (en) * 2005-07-14 2008-04-02 Pfizer Products Incorporated Process for forming amorphous azithromycin particles
CN101287706A (zh) * 2005-09-21 2008-10-15 尼科梅德有限责任公司 作为组蛋白脱乙酰基酶抑制剂的磺酰基吡咯盐酸盐
US7728129B2 (en) * 2005-10-31 2010-06-01 Janssen Pharmaceutica Nv Processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
US8558765B2 (en) * 2005-11-07 2013-10-15 Global Oled Technology Llc Method and apparatus for uniformity and brightness correction in an electroluminescent display
AU2007260356B2 (en) * 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
US7919676B2 (en) 2007-08-03 2011-04-05 Pioneer Hi-Bred International, Inc. Msca1 nucleotide sequences impacting plant male fertility and method of using same
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
US8216363B2 (en) * 2008-10-27 2012-07-10 Illinois Institute Of Technology Continuous antisolvent crystallization process and system using plug flow reactors
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
CA2754604A1 (en) 2009-03-13 2010-09-16 Da Volterra Compositions and methods for elimination of gram-negative bacteria
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
JP2013536859A (ja) * 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストの非吸湿性塩
JP2014530805A (ja) * 2011-09-30 2014-11-20 スンシネ ルアケ プハルマ カンパニー リミテッド アジルサルタンの結晶形並びにその製造及び使用
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
NZ630803A (en) * 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
IL326637A (en) * 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI7910768A8 (en) * 1979-04-02 1996-06-30 Pliva Pharm & Chem Works Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4465674A (en) * 1983-09-06 1984-08-14 Pfizer Inc. Azahomoerythromycin D derivative and intermediates therefor
RO107257B1 (ro) * 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US4983531A (en) * 1990-02-12 1991-01-08 Motorola, Inc. Method of fabricating a single polysilicon bipolar transistor which is compatible with a method of fabricating CMOS transistors
CN1093370A (zh) * 1993-12-10 1994-10-12 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
CN1034734C (zh) 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
CA2261732C (en) * 1996-07-29 2001-07-24 Abbott Laboratories Preparation of crystal form ii of clarithromycin
CN1161971A (zh) 1997-01-03 1997-10-15 石家庄制药集团有限公司 一种阿齐霉素结晶及其制备方法
PT102130A (pt) 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) * 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
US6245903B1 (en) * 1998-08-21 2001-06-12 Apotex, Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
AU768219B2 (en) * 1998-11-30 2003-12-04 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
ES2267549T3 (es) * 1999-06-29 2007-03-16 Sandoz Ag Procedimiento para la produccion de azitromicina.
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CA2396426A1 (en) 2000-01-04 2001-07-12 Teva Pharmaceutical Industries Ltd. Preparation method of azithromycin dihydrate
ES2162764B1 (es) 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
WO2002007736A1 (en) 2000-07-24 2002-01-31 Cadila Pharmaceuticals Limited The process for manufacturing of clear liquid pharmaceutical composition of azithromycin
ES2260047T3 (es) * 2000-07-25 2006-11-01 Laboratorio Silanes, S.A. De C.V. Proceso de etapa unica para la preparacion de 7,16-deoxi-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihidroxi-6-etil-3,5,9,11,13,15-hexametilbiciclo(11.2.1)hexadeca-1(2)-en-ona y obtencion de una forma nueva de 9-deoxo-9a-metil-9a-homoeritromicina a.
ITBO20000471A1 (it) 2000-07-31 2002-01-31 Vieri Ridolfi Dispositivo di supporto per prodotti da fumo particolarmente sigarette .
ES2172417B1 (es) 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
WO2002009640A2 (en) 2000-08-01 2002-02-07 Shiva Prasad Singh Process for the preparation of anhydrous azithromycin
WO2002015842A2 (en) 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
EE05200B1 (et) 2000-11-27 2009-08-17 Biochemie S.A. Asitromtsiin monohdraadina, selle valmistamismeetod ja selle kasutamine ravimkoostises
IN190080B (no) 2001-01-29 2003-06-07 Alembic Ltd
KR100431431B1 (ko) 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DK1390377T3 (da) * 2001-05-22 2006-06-19 Pfizer Prod Inc Ny krystalform af azithromycin
EP1446010B1 (en) 2001-10-18 2009-04-15 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions

Also Published As

Publication number Publication date
CR7159A (es) 2004-02-23
NO20035177D0 (no) 2003-11-21
KR100574153B1 (ko) 2006-04-25
BG108370A (bg) 2004-11-30
US6977243B2 (en) 2005-12-20
WO2002094843A1 (en) 2002-11-28
EP1390377A1 (en) 2004-02-25
DE60209704T2 (de) 2006-11-16
CA2391659A1 (en) 2002-11-22
US7053192B2 (en) 2006-05-30
NZ529118A (en) 2005-10-28
DE60209704D1 (de) 2006-05-04
MXPA03010028A (es) 2004-02-12
US7282486B2 (en) 2007-10-16
EA200301115A1 (ru) 2004-04-29
NO321894B1 (no) 2006-07-17
JP2006152002A (ja) 2006-06-15
US20040043944A1 (en) 2004-03-04
AR036022A1 (es) 2004-08-04
ATE404575T1 (de) 2008-08-15
ATE319730T1 (de) 2006-03-15
EE200300575A (et) 2004-04-15
EA007618B1 (ru) 2006-12-29
GEP20084399B (en) 2008-06-10
US20040082527A1 (en) 2004-04-29
JP2004530703A (ja) 2004-10-07
HUP0400446A2 (hu) 2004-09-28
NZ539801A (en) 2006-10-27
AU2002256846B2 (en) 2007-04-05
US7105179B2 (en) 2006-09-12
US20050090459A1 (en) 2005-04-28
CA2391659C (en) 2006-05-30
CZ20033154A3 (en) 2004-04-14
ES2310886T3 (es) 2009-01-16
KR20040014525A (ko) 2004-02-14
JP2007161726A (ja) 2007-06-28
PL367091A1 (en) 2005-02-21
AP2003002906A0 (en) 2003-12-31
BR0209918A (pt) 2004-03-30
US7307156B2 (en) 2007-12-11
MA27023A1 (fr) 2004-12-20
EP1390377B1 (en) 2006-03-08
SK14402003A3 (sk) 2004-06-08
US20040043945A1 (en) 2004-03-04
IL158591A0 (en) 2004-05-12
IS7007A (is) 2003-10-30
PA8545701A1 (es) 2003-09-05
US20050192234A1 (en) 2005-09-01
PE20021064A1 (es) 2002-11-21
EA200500630A1 (ru) 2006-02-24
MY129319A (en) 2007-03-30
EA009611B1 (ru) 2008-02-28
TNSN03121A1 (en) 2005-12-23
DE60228345D1 (de) 2008-09-25
DK1390377T3 (da) 2006-06-19
US20050256062A1 (en) 2005-11-17
PT1390377E (pt) 2006-06-30
US20030162730A1 (en) 2003-08-28
US20040138149A1 (en) 2004-07-15
US20050245469A1 (en) 2005-11-03
US7309782B2 (en) 2007-12-18
JP4584162B2 (ja) 2010-11-17
ES2258142T3 (es) 2006-08-16
YU91603A (sh) 2006-08-17
US7081525B2 (en) 2006-07-25
US20050256063A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
NO20061049L (no) Krystallformer av Azithromycin
WO2003088897A3 (en) Fab i inhibitors
HK1049656A1 (zh) Fab i抑制剂
BR0204869B1 (pt) unidade local de um aparelho de tratamento de ar e aparelho de tratamento de ar.
EP1171428A4 (en) FAB-I INHIBITORS
NO20033261D0 (no) Nye blandinger av mikrobielle enzymer
NO20053115L (no) Fremgangsmate for fremstilling av 2'-forgrenede nukleosider.
GB0125222D0 (en) Composition for the treatment of microbial infections
NO20052362D0 (no) Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner
NO20025204D0 (no) Forbindelser og fremgangsmÕter for behandling og forebygging av bakterielle infeksjoner
NO20033086D0 (no) Lineor blokk-kopolymer og fremgangsmate for fremstilling av samme
DE50306587D1 (de) Antibakterielle amid-makrozyklen
DE69913712D1 (de) Inhibitoren der bakteriellen nad synthetase
NO20043445L (no) Kombinasjonsterapi for behandling av bakterielle infeksjoner
NO20032769D0 (no) Kombinasjonsmetode for behandling av virale infeksjoner
NO20014924D0 (no) Prosess og utstyr for behandling av forurensede avgasser
ITRM20010070A0 (it) Procedimento di evoluzione controllata di vini e relativo dispositivodi attuazione.
AU2002334761A1 (en) Methods of treating drug-resistant bacterial infections
AU2001258675A1 (en) Treating infections
CA2500217A1 (en) Crystal forms of azithromycin
IS6618A (is) Hýgrómýsín A afleiður til meðhöndlunar á bakteríu- og frumdýrasýkingum
ATE459368T1 (de) Glycopeptid-antibiotika
MX342808B (es) Antibioticos de glicopeptidos.
AUPR967401A0 (en) Treatment of bacterial infections
AU2002237845A1 (en) Thioxazinoquinolones useful for the treatment of viral infections